Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of AMT-116 in Advanced Solid Tumors
NCT05725291Phase 1Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of AMT-116 in solid tumor (advanced stage), sponsored by Multitude Therapeutics. Primary endpoints: Recommended Phase 2 Dose up to 24 months, Maximum Tolerated Dose up to 24 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
AMT-116
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05725291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725291.